FY2027 Earnings Forecast for VRDN Issued By HC Wainwright

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Equities research analysts at HC Wainwright issued their FY2027 EPS estimates for Viridian Therapeutics in a research note issued on Tuesday, March 31st. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of ($3.51) for the year. HC Wainwright currently has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. HC Wainwright also issued estimates for Viridian Therapeutics’ FY2028 earnings at ($2.84) EPS, FY2029 earnings at ($1.33) EPS and FY2030 earnings at $0.71 EPS.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). The company had revenue of $0.13 million during the quarter, compared to the consensus estimate of $15.75 million. Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%.

A number of other equities research analysts also recently issued reports on VRDN. Wall Street Zen downgraded shares of Viridian Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Wedbush cut their target price on Viridian Therapeutics from $44.00 to $37.00 and set an “outperform” rating on the stock in a research note on Tuesday. The Goldman Sachs Group reduced their target price on Viridian Therapeutics from $41.00 to $36.00 and set a “buy” rating for the company in a report on Tuesday. Needham & Company LLC decreased their price target on Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating for the company in a research report on Monday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a report on Wednesday, January 21st. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $39.21.

Viridian Therapeutics Trading Down 1.6%

NASDAQ VRDN opened at $18.84 on Thursday. The firm has a market capitalization of $1.93 billion, a P/E ratio of -5.73 and a beta of 1.16. The business has a fifty day simple moving average of $28.63 and a 200 day simple moving average of $27.77. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $34.29. The company has a current ratio of 12.65, a quick ratio of 12.65 and a debt-to-equity ratio of 0.08.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VRDN. Vanguard Group Inc. grew its stake in Viridian Therapeutics by 29.6% in the 4th quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock valued at $174,650,000 after buying an additional 1,280,161 shares in the last quarter. Commodore Capital LP lifted its position in shares of Viridian Therapeutics by 35.4% during the second quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock worth $68,152,000 after acquiring an additional 1,275,000 shares in the last quarter. State Street Corp lifted its position in shares of Viridian Therapeutics by 35.7% during the fourth quarter. State Street Corp now owns 3,466,560 shares of the company’s stock worth $107,879,000 after acquiring an additional 912,394 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Viridian Therapeutics by 42.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,439,414 shares of the company’s stock worth $107,036,000 after acquiring an additional 1,021,310 shares during the period. Finally, Perceptive Advisors LLC boosted its holdings in shares of Viridian Therapeutics by 108.1% in the fourth quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock worth $94,689,000 after acquiring an additional 1,580,303 shares during the period.

Viridian Therapeutics News Roundup

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Topline REVEAL-1 Phase III results reported clinical activity for elegrobart — supports the drug’s efficacy and preserves an approval/commercial pathway, which is a material long-term positive for VRDN. Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript
• Positive Sentiment: Some analysts remain constructive on longer-term upside: HC Wainwright maintains a Buy and has modeled recovery into FY2029–2030 (including a FY2030 EPS projection), reflecting belief in commercial potential beyond near-term noise. (Market commentary / analyst note summaries)
• Neutral Sentiment: Short-term trading has been volatile — the stock saw large swings on volume as the market digested nuanced efficacy/market-position takeaways; that raises short-term uncertainty but also increases liquidity for active traders. Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?
• Negative Sentiment: Market reaction included a sharp pre-market drop (reported ~41% at one point) as investors judged the results insufficiently dominant versus competitors and priced in execution/market-share risk. VRDN stock plummeted 41% pre-market today — what did its phase 3 active thyroid eye disease trial reveal?
• Negative Sentiment: Several firms lowered expectations/targets after the readout: Goldman cut its price target, Wells Fargo trimmed its target to $20, and other notes signaled more cautious near-term forecasts — increasing near-term downside risk from analyst-driven flows. The Goldman Sachs Group Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 Wells Fargo & Company Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $20.00 Wedbush Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price
• Negative Sentiment: Critical takes emphasize that REVEAL-1 returned clinically meaningful but not clearly market-dominant data, which may limit peak sales vs. competitors and lengthen the commercialization ramp — a negative for near- to medium-term valuation. Viridian’s REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.